Literature DB >> 29345199

Pulmonary vascular dysfunction secondary to pulmonary arterial hypertension: insights gained through retrograde perfusion.

Chun Zhou1,2, Edward S Crockett3,2, Lynn Batten4, Ivan F McMurtry3,5,2, Troy Stevens1,5,2.   

Abstract

Here, we tested the hypothesis that severe pulmonary arterial hypertension impairs retrograde perfusion. To test this hypothesis, pulmonary arterial hypertension was induced in Fischer rats using a single injection of Sugen 5416 followed by 3 wk of exposure to 10% hypoxia and then 2 wk of normoxia. This Sugen 5416 and hypoxia regimen caused severe pulmonary arterial hypertension, with a Fulton index of 0.73 ± 0.07, reductions in both the pulmonary arterial acceleration time and pulmonary arterial acceleration to pulmonary arterial ejection times ratio, and extensive medial hypertrophy and occlusive neointimal lesions. Whereas the normotensive circulation accommodated large increases in forward and retrograde flow, the hypertensive circulation did not. During forward flow, pulmonary artery and double occlusion pressures rose sharply at low perfusion rates, resulting in hydrostatic edema. Pulmonary arterial hypertensive lungs possessed an absolute intolerance to retrograde perfusion, and they rapidly developed edema. Retrograde perfusion was not rescued by maximal vasodilation. Retrograde perfusion was preserved in lungs from animals treated with Sugen 5416 and hypoxia for 1 and 3 wk, in lungs from animals with a milder form of hypoxic hypertension, and in normotensive lungs subjected to high outflow pressures. Thus impaired retrograde perfusion coincides with development of severe pulmonary arterial hypertension, with advanced structural defects in the microcirculation.

Entities:  

Keywords:  edema; plexiform lesions; pulmonary hypertension; semaxanib (Sugen 5416); vascular resistance

Mesh:

Year:  2018        PMID: 29345199      PMCID: PMC6008136          DOI: 10.1152/ajplung.00201.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  46 in total

1.  Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema.

Authors:  A C GUYTON; A W LINDSEY
Journal:  Circ Res       Date:  1959-07       Impact factor: 17.367

Review 2.  Emerging therapies for the treatment of pulmonary hypertension.

Authors:  Kurt R Stenmark; Marlene Rabinovitch
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

Review 3.  Studies on the cell biology of interendothelial cell gaps.

Authors:  Cristhiaan D Ochoa; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

4.  Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.

Authors:  Syed H E Zaidi; Xiao-Mang You; Sorana Ciura; Mansoor Husain; Marlene Rabinovitch
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

5.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

Review 6.  The Evolving Classification of Pulmonary Hypertension.

Authors:  Michelle Foshat; Nahal Boroumand
Journal:  Arch Pathol Lab Med       Date:  2017-03-16       Impact factor: 5.534

7.  Single arterial occlusion to locate resistance in patients with pulmonary hypertension.

Authors:  P Fesler; A Pagnamenta; J L Vachiéry; S Brimioulle; S Abdel Kafi; A Boonstra; M Delcroix; R N Channick; L J Rubin; R Naeije
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

8.  Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery.

Authors:  C A Wagenvoort; N Wagenvoort; Y Draulans-Noë
Journal:  J Thorac Cardiovasc Surg       Date:  1984-06       Impact factor: 5.209

9.  Pulmonary microvascular endothelial cells form a tighter monolayer when grown in chronic hypoxia.

Authors:  Victor Solodushko; James C Parker; Brian Fouty
Journal:  Am J Respir Cell Mol Biol       Date:  2007-11-29       Impact factor: 6.914

Review 10.  Cellular and molecular basis of pulmonary arterial hypertension.

Authors:  Nicholas W Morrell; Serge Adnot; Stephen L Archer; Jocelyn Dupuis; Peter Lloyd Jones; Margaret R MacLean; Ivan F McMurtry; Kurt R Stenmark; Patricia A Thistlethwaite; Norbert Weissmann; Jason X-J Yuan; E Kenneth Weir
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

View more
  6 in total

Review 1.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

2.  A cancer amidst us: the plexiform lesion in pulmonary arterial hypertension.

Authors:  Ji Young Lee; C Michael Francis; Natalie N Bauer; Natalie R Gassman; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-19       Impact factor: 6.011

3.  The role of endothelial leak in pulmonary hypertension (2017 Grover Conference Series).

Authors:  Chun Zhou; C Michael Francis; Ningyong Xu; Troy Stevens
Journal:  Pulm Circ       Date:  2018-08-20       Impact factor: 3.017

4.  KD025 Shifts Pulmonary Endothelial Cell Bioenergetics and Decreases Baseline Lung Permeability.

Authors:  Ji Young Lee; Reece P Stevens; Mary Kash; Chun Zhou; Anna Koloteva; Phoibe Renema; Sunita S Paudel; Troy Stevens
Journal:  Am J Respir Cell Mol Biol       Date:  2020-10       Impact factor: 6.914

5.  Never Change a Flowing System? The Effects of Retrograde Flow on Isolated Perfused Lungs and Vessels.

Authors:  Hanif Krabbe; Sergej Klassen; Johannes Bleidorn; Michael J Jacobs; Julia Krabbe; Aaron Babendreyer; Christian Martin
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

6.  Biventricular diastolic dysfunction, thrombocytopenia, and red blood cell macrocytosis in experimental pulmonary arterial hypertension.

Authors:  Ji Young Lee; Karen A Fagan; Chun Zhou; Lynn Batten; Michael V Cohen; Troy Stevens
Journal:  Pulm Circ       Date:  2020-05-26       Impact factor: 3.017

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.